CompletedPhase 2

Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome

Egypt60 participantsStarted 2006-06

Plain-language summary

The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).

Who can participate

Age range19 Years – 37 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a minimum of three consecutive pregnancy losses before 10 weeks gestation * Positive lupus anticoagulant and/or anticardiolipin antibodies (IgG and IgM) on at least two occasions twelve weeks apart . * Age between 19 - 37 years, * Body mass index between 19-30 Exclusion Criteria: * Parental chromosomal abnormalities * Uterine abnormalities * Luteal phase defect * Systemic lupus erythematosus * Previous thromboembolism * Sensitivity to aspirin.

What they're measuring

Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

Timeframe: pregnancy > 24weeks gestation

Trial details

NCT IDNCT01051778

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-11

Results submitted2010-05-10

View on ClinicalTrials.gov More Recurrent Abortion trials